China’s SIMM, French Drugmaker Servier To Collaborate On Anti-Tumor Medicine R&D
This article was originally published in PharmAsia News
Shanghai Institute of Materia Medica (SIMM) and French pharmaceutical company Servier Laboratories signed an agreement on the R&D of targeted antitumor drug candidate lucitanib.
You may also be interested in...
News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.